Page 11 - Flipbook

Summary of the recommendations for

clinicians and policy makers

For men aged 55-69 years, we recommend not screening for
prostate cancer with the PSA test.

(Weak recommendation; moderate quality evidence)

Basis of the recommendation

• The CTFPHC placed a relatively low value on a small and uncertain

potential reduction in the risk of prostate cancer mortality and a

relatively higher value on the risk of false positive results,

unnecessary biopsy and overdiagnosis, and harms of unnecessary

treatment.

• The weak recommendation against screening implies that the

harms of screening and subsequent testing/treatment probably

outweigh benefits, but uncertainty exists.

14